We next determined the level of p50/p65 in the cell lysate, and found that vemurafenib (2.5 μM) or melatonin (1 mM) treatment alone reduced the expression of p50/p65 in the nuclei of melanoma cells (Fig. 4c), and the treatment with melatonin and vemurafenib markedly inhibited translocation of the NF-κB p65/p50 proteins from cell cytoplasm to nucleus by comparison with the control treatment group (Fig. 4c, d). The gene discussed is NFKB1; the disease is melanoma.